Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell, Cutaneous 8Mycosis Fungoides 7Sezary Syndrome 5Carcinoma, Non-Small-Cell Lung 5Lymphoma 3Leukemia, Myeloid, Acute 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lung Neoplasms 2Leukemia 2Carcinoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Sarcoma, Kaposi 1Recurrence 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1HIV Infections 1Congenital Abnormalities 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Anemia, Refractory, with Excess of Blasts 1Aggression 1Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Bexarotene × Clear all
NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

National Cancer Centre, Singapore

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡